Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical (LFCR) Research & Development: 2009-2025

Historic Research & Development for Lifecore Biomedical (LFCR) over the last 15 years, with May 2025 value amounting to $2.1 million.

  • Lifecore Biomedical's Research & Development fell 2.68% to $2.1 million in Q2 2025 from the same period last year, while for May 2025 it was $8.3 million, marking a year-over-year decrease of 3.70%. This contributed to the annual value of $8.3 million for FY2025, which is 3.70% down from last year.
  • According to the latest figures from Q2 2025, Lifecore Biomedical's Research & Development is $2.1 million, which was up 2.84% from $2.0 million recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical's Research & Development registered a high of $2.3 million during Q1 2022, and its lowest value of $1.6 million during Q1 2021.
  • Its 3-year average for Research & Development is $2.1 million, with a median of $2.1 million in 2023.
  • Data for Lifecore Biomedical's Research & Development shows a peak YoY increase of 312.50% (in 2021) and a maximum YoY decrease of 40.41% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows Lifecore Biomedical's Research & Development stood at $1.7 million in 2021, then grew by 29.58% to $2.2 million in 2022, then declined by 3.63% to $2.1 million in 2023, then dropped by 8.29% to $1.9 million in 2024, then dropped by 2.68% to $2.1 million in 2025.
  • Its last three reported values are $2.1 million in Q2 2025, $2.0 million for Q1 2025, and $1.9 million during Q4 2024.